Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process.

Objective. During osteoarthritis (OA), the altered metabolism of cartilage involves proinflammatory factors and matrix metalloprotease (MMP) activity. Studies showed that chondroitin sulfate (CS) may exert a positive effect on the cartilage. Because of differences in CS in terms of purity and theproduction/purification process, we compared the effects of 3 different types of CS on human OA cartilage. Methods. Three types of CS were tested: CS1 (porcine, purity 90.4%). CS2 (bovine, purity 96.2%), and CS3 (bovine, purity 99.9%). Treatment with CS at 200 and 1000 mu g/ml was performed on human OA cartilage explants in the presence/absence of interleukin 1 beta (IL-1 beta), and the protein modulations of factors including prostaglandin E-2 (PGE(2)), IL-6, and MMP-1 measured by ELISA. The CS effect on the expression of collagen type II was also investigated on OA chondrocytes using quantitative polymerase chain reaction. Results. In the presence of IL-1 beta, CS2 at 1000 mu g/ml significantly inhibited IL-6 and PGE(2) production. and CS3 at 200 mu g/ml markedly reduced the level of IL-6. CS1 was much less efficient at reducing the catabolic markers and in the absence of IL-1 beta. it significantly increased IL-6 and MMP-1. IL-1 beta significantly inhibited the gene expression level of collagen type II; only CS3 was able to limit this inhibition. CS1, in the presence or absence of IL-I beta, further markedly decreased collagen type II expression. Conclusion. Our data indicate that among the 3 tested CS, CS1 increased production of some catabolic pathways and inhibited the gene expression level of collagen type II. Our study provides new information in the context of prescribing CS for alleviating CA symptoms, as the purity and/or production/purification of the CS compound could orient the current OA disease process toward increased catabolic pathways. (First Release Feb 1 2010; J Rheumatol 2010;37:656-64; doi: 10.3899/jrheum.090696)